Fingerprint
Dive into the research topics of 'Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
Carlo Gambacorti-Passerini, Jorge E. Cortes, Jeff H. Lipton, Anna Dmoszynska, Raymond S. Wong, Victor Rossiev, Dmitri Pavlov, Karin Gogat Marchant, Ladan Duvillié, Navin Khattry, Hagop M. Kantarjian, Tim H. Brümmendorf
Research output: Contribution to journal › Article › peer-review
85
Scopus
citations